---
action_items:
- id: c412dd907b79
  severity: writing
  text: The claim that EywaAgent improves utility by ~7% (Introduction) is inconsistent
    with Table 1 (0.6558 vs 0.6154, ~6.6%). While close, the text should match the
    reported table value or clarify the rounding method to ensure factual precision.
- id: 1a49192391cc
  severity: writing
  text: The claim that Eywa reduces token usage by ~30% (Introduction) is supported
    by Table 1 (4469 vs 3137 tokens, ~29.8%). However, the text states 'nearly 30%'
    in Section 5.3 but 'reducing token usage by ~30%' in the Introduction. Ensure
    consistency in phrasing or precision across sections.
- id: b61ec986a696
  severity: writing
  text: The claim that EywaOrchestra 'surpasses' EywaMAS on several sub-domains (Section
    5.3) is not fully supported by Table 1. EywaOrchestra has higher utility than
    EywaMAS in Space (0.7187 vs 0.6899), Clinic (0.5159 vs 0.5086), Drug (0.6319 vs
    0.6248), and Business (0.7388 vs 0.7284). However, the text says 'surpasses it
    on several sub-domains' which is accurate, but the phrasing 'surpasses it' might
    imply a general trend. Clarify if this is limited to specific domains.
- id: 2dcbcb4dbb10
  severity: writing
  text: The claim that 'heterogeneous LLM-only MAS methods do not consistently outperform
    strong homogeneous MAS baselines' (Section 5.3) is supported by Table 1 (MoA and
    X-MAS have lower utility than Refine and Debate in most domains). However, the
    text should explicitly reference the specific baselines (Refine, Debate) to avoid
    ambiguity about which 'strong homogeneous MAS baselines' are being compared.
- id: d2f49c099628
  severity: writing
  text: The claim that 'EywaAgent improves both quality and efficiency under the same
    backbone' (Section 5.3) is supported by Table 1 (0.6558 utility vs 0.6154, 3137
    tokens vs 4469). However, the text should clarify that this comparison is against
    the 'Single-LLM-Agent' baseline (gpt-5-nano) to avoid confusion with other baselines.
artifact_hash: 6f6f16bf33fe17a682df44afbf900ee0d80c1586f03954b67f158a9d54f94900
artifact_path: projects/PROJ-573-https-arxiv-org-abs-2604-27351/paper/metadata.json
backend: dartmouth
feedback: ''
github_authenticated: false
model_name: qwen.qwen3.5-122b
prompt_version: 1.1.0
reviewed_at: '2026-07-01T23:49:29.043256Z'
reviewer_kind: llm
reviewer_name: paper_reviewer_claim_accuracy
score: 0.0
verdict: minor_revision
---

The paper makes several quantitative claims about performance improvements (utility, token usage, latency) that are generally supported by the data in Table 1 and the appendix. However, there are minor inconsistencies in the precision of reported percentages and the specificity of comparisons that should be addressed for factual accuracy.

In the Introduction, the claim that EywaAgent improves utility by "~7%" is slightly imprecise compared to the table value of 6.6% (0.6558 vs 0.6154). While this is a minor rounding difference, the text should either use the exact value or clarify the rounding convention. Similarly, the token reduction claim of "~30%" is accurate (29.8%), but the phrasing should be consistent across sections (e.g., "nearly 30%" in Section 5.3 vs "~30%" in the Introduction).

The claim that EywaOrchestra "surpasses" EywaMAS on "several sub-domains" is factually correct based on Table 1 (Space, Clinic, Drug, Business), but the phrasing could be misinterpreted as a general trend. Clarifying that this is limited to specific domains would improve precision. Additionally, the claim about heterogeneous LLM-only MAS methods not outperforming homogeneous baselines should explicitly name the baselines (Refine, Debate) to avoid ambiguity.

Finally, the claim that EywaAgent improves quality and efficiency "under the same backbone" is supported, but the text should explicitly reference the "Single-LLM-Agent" baseline (gpt-5-nano) to ensure clarity about the comparison. These are minor issues that can be resolved with precise wording adjustments.
